Sign up to our newsletter Subscribe
We found for
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
